Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer
Ki Hyeong Lee, Jung Shin Lee, Sang‐We Kim et al. · European Journal of Cancer · 2013
Cited by 77 works. doi:10.1016/j.ejca.2013.06.035
Authors
- Ki Hyeong Lee
- Jung Shin Lee
- Sang‐We Kim
- José Rodrigues Pereira
- Baohui Han
- Xiangqun Song
- Jie Wang
- Hoon-Kyo Kim
- Raghunadharao Digumarti
- Xin Wang
- Sedat Altuǧ
- Mauro Orlando
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
- Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
- Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer